Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 6, 2015
February 9, 2019
47c1576a-8db7-49fb-8fcc-66e1d013145e
Related Documents
Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
Guidance DocumentJuly 31, 2026Center for Drug Evaluation and Research
Drug Interaction Information in Human Prescription Drug and Biological Product Labeling
Guidance DocumentOctober 21, 2024Center for Drug Evaluation and Research
Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products—Recommended Practices
Guidance DocumentJune 11, 2014Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.